Roswell Park Metastatic Breast Cancer Studies Focus on New Immunotherapies

Mateusz Opyrchal, MD, PhD
Published: Tuesday, Apr 30, 2019
VCUMateusz Opyrchal, MD, PhD
Mateusz Opyrchal, MD, PhD
Assistant Professor of Medicine
Associate Director of the Early Phase Clinical Trials Program
Co-leader of the Adoptive Cellular Therapy Program
Co-leader of the Breast Disease Specific Research Group at Roswell Park Comprehensive Cancer Center, Buffalo, New York 
Strategic Partnership
Despite considerable advances and promising developments in recent years, metastatic breast cancer (mBC) continues to be a deadly disease. Although the first immune agonist was recently approved for patients with locally advanced or metastatic triple-negative breast cancer (mTNBC), the effectiveness of immunotherapy strategies in the treatment of mBC remains a work in progress.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication